- Home
- HBNC vs ERAS Comparison
HBNC vs ERAS Comparison
Compare HBNC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBNC | ERAS |
|---|---|---|
| Founded | 1873 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 1.0B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HBNC | ERAS |
|---|---|---|
| Price | $16.48 | $15.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $20.33 | $5.78 |
| AVG Volume (30 Days) | 343.9K | ★ 3.3M |
| Earning Date | 03-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ 25.00 | 16.87 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.78 | N/A |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.70 | $1.01 |
| 52 Week High | $19.07 | $15.27 |
Technical Indicators
Market Signals| Indicator | HBNC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 78.09 |
| Support Level | $15.74 | $1.27 |
| Resistance Level | $16.58 | N/A |
| Average True Range (ATR) | 0.57 | 0.81 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 5.18 | 89.80 |
Price Performance
Historical ComparisonAbout HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.